CURATIS N AG

Curatis Holding AG acquires, develops, and commercializes medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. Its products cover areas such as fentanyl, breakthrough pain, antiplatelet therapy, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, Wilson's disease, cyanide poisoning, digoxin toxicity, antihypotensive, bladder pain syndrome/interstitial cystitis, antibioticum, diagnostic ophthalmology, antiviral, ophthalmic/antibioticum, gentamycin collagen sponge, benign prostatic hyperplasia, immunomodulator, epilepsy and essential tremor, thyreostatic, hereditary tyrosinemia type 1, nootropic, tranquilizer, Helicobacter pylori test, phosphate binder, special nutrition for dialysis patients, dermato corticosteroid, lead and mercury poisoning, corticostimulin, anti-fog agent, chorea associated with Huntington's disease, and antiepileptic. The company also develops C-PTBE-01 in Phase IIb for peritumoral brain edema, C-AM-01 in Phase IIa for prevention of severe migraine with aura, C-MOH-01 in Phase IIa for treatment and prevention of medication overuse headache, and C-FI-01 in Phase I for fibrotic or inflammatory orphan or ultra-orphan diseases. Founded in 2002, it is based in Liestal, Switzerland.